Research & DevelopmentAccording to research, Gilead's long-acting HIV medication is superior...

According to research, Gilead’s long-acting HIV medication is superior to Truvada

-

Gilead Sciences (GILD.O) announced that in a late-stage trial, its injectable treatment, lenacapavir, was 40.2% more effective in preventing HIV than the current daily pill, Truvada. Gilead noted that there were no cases of HIV infections during the study period for all the women who took lenacapavir.

No new safety concerns were identified with lenacapavir, and the compound was assessed as very well tolerated by the company. Further details on safety and efficacy will be provided at an upcoming scientific conference. It is estimated that 1.2 million people are living with HIV in the United States, as reported by the CDC.

Tenofovir/emtricitabine, sold under the brand name Truvada, is used in the treatment of HIV and also as a prevention strategy for healthy people at risk of contracting the virus, known as pre-exposure prophylaxis or PrEP. Currently, the CDC reports that PrEP can decrease the chances of getting HIV through sexual contact by approximately 99%.

Lenacapavir, known as Sunlenca, is administered every six months. It received FDA approval in 2022 due to its long-acting formulation and is used for patients with heavily pre-treated HIV and multi-drug resistant virus.

In the study, over 5,300 cisgender women and adolescent girls aged 16-25 were administered lenacapavir, Descovy, or Truvada.

Descovy, a once-daily tablet, was approved in 2019 for pre-exposure prophylaxis of HIV in MSM and transgender women, along with condoms, to prevent sexually-acquired HIV infection.

Gilead stated that the company is awaiting the outcomes of another phase 3 trial in men who have sex with men (MSM), transgender men, transgender women, and gender non-binary individuals who have sexual relations with male partners. The results are expected in the last quarter of 2024 or early 2025 regarding the use of lenacapavir for PrEP.

Life Sciences Voice Logo mobile
+ posts

Latest news

Top 10 Strategic Priorities for Pharmaceutical Leaders in 2026

Executive Summary The pharmaceutical industry is entering a period of profound transformation. While scientific innovation remains the foundation of long-term...

Why Data Quality Is Becoming Pharma’s Biggest AI Challenge

Executive Summary Artificial intelligence (AI) has become one of the pharmaceutical industry's most important strategic priorities. Companies are investing heavily in...

Lilly challenges J&J in the market for psychedelic mental health by paying $2.8 billion up front for AtaiBeckley

Eli Lilly has inked the deal to purchase AtaiBeckley for $2.8 billion to continue its acquisition spree in a...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you